Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Analysts at Citizens Jmp

Citizens Jmp started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note published on Monday, MarketBeat Ratings reports. The firm issued an outperform rating and a $51.00 price target on the stock.

Other research analysts have also issued reports about the company. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price objective on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price for the company. Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research report on Thursday, May 28th. Leerink Partners started coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Weiss Ratings began coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $54.00.

Sensei Biotherapeutics Stock Up 9.0%

Sensei Biotherapeutics stock opened at $28.19 on Monday. Sensei Biotherapeutics has a 52-week low of $6.32 and a 52-week high of $37.90. The firm has a market capitalization of $37.77 million, a PE ratio of -0.20 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Research analysts anticipate that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In related news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Brian C. Stephenson acquired 5,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was purchased at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This represents a 11.99% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 49,494 shares of company stock valued at $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth about $22,758,000. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics during the 1st quarter valued at approximately $4,188,000. Finally, Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.